Severe erectile dysfunction is a marker for hyperprolactinemia
|
|
- Victor Shaw
- 5 years ago
- Views:
Transcription
1 (2001) 13, 176±182 ß 2001 Nature Publishing Group All rights reserved /01 $ Severe erectile dysfunction is a marker for hyperprolactinemia AM Johri 1, JPW Heaton 1 * and A Morales 1 1 Queen's University, Kingston General Hospital, Ontario, Canada The need for routine prolactin (PRL) measurement in the initial evaluation of erectile dysfunction (ED) has been questioned because of the low rate of hyperprolactinemia (HP) in these men and the costs involved. In addition, it is widely thought that sexual desire problems are a good clinical marker for HP and=or low testosterone in men with ED. Within a 15-month period, 844 consecutive PRL and sexual hormone determinations were conducted in men at the Kingston General Hospital. Of these patients, 138 were comprehensively evaluated at the rst visit for ED and completed the International Index of Erectile Function (IIEF). In the 138 patients, 2.2% had severe hyperprolactinemia (>35 ng=ml), within the range of 1 ± 5% previously reported. No correlation between initial prolactin value and the sexual desire domain or the erectile function domain (EFD) of the IIEF was found for this population. However, all cases of severe HP were found to occur in men who scored less than 10 in the EFD of the IIEF. Low libido is widely accepted as a marker of HP. In this study, HP was found in patients not reporting major problems with a desire disorder. Clinically signi cant HP may be reliably found with routine biochemical evaluation and in this series was not detected in patients with EFD scores above 10. A routine PRL measurement is inexpensive and early detection of a serious and treatable disease may afford greater therapeutic success. (2001) 13, 176±182. Keywords: prolactin; erectile dysfunction; libido; routine measurement Introduction The need for routine prolactin measurement in the initial evaluation of erectile dysfunction (ED) has been questioned because of the low rate of hyperprolactinemia (HP) in these men and the cost of conducting routine measurements. 1,2 Furthermore, it is commonly accepted that poor libido is an adequate clinical marker for HP and=or low testosterone in men with ED and so may serve as the basis for selective prolactin (PRL) determinations. 3,10 This is based on the observation that decreased libido levels may be correlated to increases in that individual's PRL level. However can a single initial assessment of libido be predictive of HP for any given man presenting with ED? If so, then the initial libido status can be used to conduct selective PRL measurements. To address this question, we have compared the initial libido status (using various indices of sexual desire) with corresponding initial PRL levels of men with ED. To address the cost of routine PRL measurements, we have determined the prevalence of HP and calculated the cost of detecting a single case in the ED clinic. *Correspondence: JPW Heaton, MD, Queen's University, Kingston General Hospital, 76 Stuart Street, Kingston, Ontario, Canada, K7L 2V7. Received 1 August 2000; accepted 26 February 2001 The increased availability of effective treatments for ED which do not address the underlying disease presents a challenge to the accurate diagnosis of ED. 4 There are now reports indicating that successful treatment of ED may occur despite potentially signi cant HP. 5 A case of missed HP in which sildena l improved sexual function has been described. 5 To demonstrate the value of routine PRL measurement in all men presenting to the ED clinic, this report presents an additional case of a man whose ED initially improved with sildena l. The result from the routine PRL measurement was investigated at a later time and indicated that the underlying cause of his ED was in fact HP. Materials and methods Within a 15-month period (4 January 1999 ± 13 April 2000), 844 consecutive PRL and sexual hormone determinations were conducted in men at the Kingston General and af liated Queen's University hospitals. Three hundred and seventy-four of these men were examined by a physician for a urological condition. Of these men, 138 were comprehensively evaluated at the rst visit for ED and completed the International Index of Erectile Function (IIEF). 6 A thorough sexual, medical and psychosocial history
2 was taken and a focused physical examination was performed on every patient with ED. 7 Eighty-seven patients also answered a single question asked by an experienced interviewer in a customized inventory (CI) of sexual status designed to ascertain the libido level (increased, stable, or decreased). ED was de ned as dif culty in initiating and=or maintaining an adequate erection to effect penetration and ejaculation. 8 Erectile function and sexual desire were determined by the Erectile Function Domain (EFD) and Sexual Desire Domain (SDD) of the IIEF. All men presenting to the ED clinic had a routine PRL measurement conducted at the rst visit. All serum values were obtained by the Kingston General Hospital Biochemistry Laboratory. Free and total testosterone, luteinizing hormone (LH), follicular stimulating hormone (FSH) and glucose were measured using standard techniques. PRL was measured using the Bayer Immuno 1 Automated Immunoassay Instrument (Tarrytown, NY). The total number of men with high PRL levels requiring treatment were reported. Characteristics of all found cases were evaluated. One instructive case of missed HP, initially treated with sildena l is described in full. The total cost of conducting a routine PRL measurement, and the cost of detecting a single case of true HP in the 138 patients was calculated. We also analysed data from a new group of patients presenting to the ED clinic from January 1997 to January 1999, in order to con rm our initial ndings. Results The average PRL levels per decade for 427 determinations (374 patients) ordered in association with a urological condition was determined as detailed in Table 1. Complete PRL and IIEF scores were available for 138 cases. Three patients out of these 138 (2.2%) had PRL levels above 35 ng=ml which corresponds to markedly high or severe hyperprolactinemia. 2 Six patients out of 138 had mild HP de ned as being 15 ± 35 ng=ml. 2 A statistical correlation between initial testosterone and PRL levels was not found for the group of men with ED (Figure 1). However, all cases of severe HP were found to occur below 10 nmol=l. Many hypogonadals were found not to have HP. Four out of six cases of mild HP were found to occur within the normal range of testosterone. There was no statistical correlation between the initial SDD score and testosterone levels for this population of men (Figure 2A). Although PRL is commonly associated with low desire in individuals, 2,10 the initial SDD scores for this population were not found to correlate with the corresponding PRL levels obtained (Figure 2B). The three cases of severe HP found were associated with a SDD score of less than 5. Testosterone levels were not statistically correlated with the EFD score (Figure 2C). A surprising relationship between PRL and erectile function was found. All men with mild and severe HP were found to have an EFD score below 10, suggesting a clinically important effect of PRL on erectile function (Figure 2D). To con rm these ndings, a new group of patients was analysed. Analysis of PRL levels determined between 1997 and 4 January 1999 revealed that all cases of HP were again found to occur in men who scored less than 10 in the EFD of the IIEF (Figure 2D). This study revealed no statistical correlation between the initial SDD score of the IIEF and PRL, but can a correlation be found using an alternate index of desire? Data generated from the single question (`Is your libido decreased?') in a CI of sexual status was available for 87 patients. The average PRL levels in patients reporting decreased libido in the CI was not signi cantly different from those reporting normal libido (Figure 3A). This suggests that the CI, and again the initial desire 177 Table 1 Mean and median prolactin distribution by decade for patients assessed for a urological condition in a 15-month period Patient age Total no patients (no of prolactin determinations)* Prolactin ng=ml Mean (ranges) Median 21 ± 30 5 (5) 5.1 (3.3 ± 6.7) ± (23) 8.8 (2.8 ± 20.3) ± (72) 10.0 (1.7 ± 164.4) ± (130) 5.2 (1.9 ± 23.9) ± (125) 13.2 (1.2 ± 366) ± (66) (0.1 ± 4235) ± 90 6 (6) 8.6 (5.2 ± 16.1) 6.4 Totals 374 (427) *Some patients had repeat prolactin determinations. The means are obtained from all prolactin determinations. Figure 1 Scatter plot of testosterone values and corresponding prolactin levels measured in 138 men presenting to the Erectile Dysfunction Clinic.
3 178 Figure 2 (A) Scatter plot of testosterone levels with the corresponding score from the sexual desire domain of the IIEF (January 1999 to April 2000, n ˆ 138). (B) Scatter plot of prolactin levels with corresponding scores from the sexual desire domain of the IIEF (January 1999 to April 2000, n ˆ 138). (C) Scatter plot of testosterone levels with corresponding score from the erectile function domain of the IIEF (January 1999 to April 2000, n ˆ 138). (D) Scatter plot of prolactin levels with the corresponding score from the erectile function domain of the IIEF. status, were not predictive of PRL levels in this study. As expected, the average SDD score of patients reporting decreased libido in response to the CI was lower than the average score of patients reporting normal libido (Figure 3B). The average EFD score from the IIEF of patients reporting decreased libido in the CI was not signi cantly different from those patients reporting normal libido in the CI (Figure 3C). The average testosterone level in patients reporting decreased libido was not signi cantly different from those reporting normal libido (Figure 3D). In summary, the psychometric indices of desire and erectile function used routinely by our clinic were not predictive of HP or hypogonadism. However, all cases of HP occurred in patients with an EFD score below 10. Case study The patient was a 50-y-old white man with no signi cant past medical history who was referred to the ED clinic. The patient presented with poor sexual function in a new relationship with a signi cant anxiety interaction component. The IIEF scores were rated as follows: Erectile Function Domain (6=30), Orgasmic Function Domain (2=10), Sexual Desire Domain (4=10), and Intercourse
4 Satisfaction Domain (4=15). The man reported normal libido in response to the CI of sexual status. General chemistry revealed low total testosterone (3.0 nmol=l) and high PRL (164.4 mg=l) levels. Repeat determination con rmed these values. PSA and DHEAS were within normal limits. A trial of sildena l treatment (Viagra TM, P zer, NY) was prescribed. Sildena l treatment resulted in an immediate improvement in erectile function. Once the PRL level had been con rmed, a CT scan was conducted. The CT could not rule out a microadenoma and so the patient's therapy was switched 179 Figure 3 Libido status as determined by the single question (`Is your libido decreased or normal?') in a customized inventory of sexual status compared with clinical indices. (A) Average prolactin level and libido (n ˆ 87). (B) Average Sexual Desire Domain score and libido (n ˆ 87). (C) Average Erectile Function Domain score and libido (n ˆ 87). (D) Average testosterone and libido (n ˆ 87).
5 180 to bromocriptine. Within 2 weeks of bromocriptine treatment (2.5 mg), the patient's sexual function was improved in all respects as identi ed by patient and partner. After 4 weeks of bromocriptine therapy the IIEF score was rated as 30=30 for the EFD without any use of sildena l. PRL levels were stabilized within the normal range. The patient elected to remain on bromocriptine therapy. Discussion Consensus on the role of routine PRL measurement in the initial evaluation of men with ED has not been established. Akpunonu et al evaluated the prevalence of HP in 212 impotent men and found the prevalence too low (1.4%) to justify a routine PRL screen at their institutional charge of $57 for each determination. 1 Selective determination in patients with low testosterone was suggested. We were unable to t a curve to the initial testosterone levels and corresponding PRL levels for a population of men with ED. Testosterone may fall as PRL rises in an individual, but for our population of men, the initial testosterone level was not predictive of the PRL level. As seen in Figure 1A, several men with low initial testosterone levels had normal or low PRL levels. Determination of PRL only in the case of markedly low initial testosterone (below 4 nmol=l) would have missed ve of the six cases of mild HP and two of the three cases of severe HP. Determination in cases of testosterone below 10 nmol=l would have encompassed all cases of severe but not mild HP. Johnson et al found a prevalence of 2.1% for HP in 330 impotent patients and recommended screening men only with low libido or bilateral testicular atrophy considering that their cost for a PRL level was $92. 9 We found a similar prevalence of severe HP (2.2%) but no clear association between libido and PRL at the population level. HP has been associated with loss of libido in individuals, 10 but can an initial assessment of libido on its own predict whether an individual will have de ned HP? We found that if determining PRL only in cases of low sexual desire (SDD score below 3), more than 50% of the cases of HP would have been missed. Measuring PRL when the SDD was 5 or below would encompass the cases of severe but not mild HP. When applied to a population of men with ED, the SDD of the IIEF and the direct questions about sexual desire and libido (the CI) do not select for patients likely to have high PRL. Within an individual, the changes in the SDD or CI may be so striking when the HP is treated that there is no doubt about the link, for that individual, between PRL and libido. However these instruments appear not to be precise enough, and PRL, libido, and testosterone are subject to so many unrelated in uences, such that the instruments have no discriminatory value in terms of deciding when to measure serum PRL at rst contact. In keeping with the distinction made between an individual and a population of men with ED, we were unable to nd a statistical correlation between the initial EFD score of the IIEF and PRL levels for the group studied. However, 100% of the cases of mild to severe HP were found to occur in men who scored less than 10 in the EFD of the IIEF questionnaire. This score has been shown to agree with a severe degree of ED. 11 Though a low EFD score is not predictive of HP (many more men with low scores had normal to low PRL, Figure 2D), this value serves as a useful cut-off point, below which, one cannot elect to forgo PRL determination. When evaluating the association between HP and disease, it must be considered that several PRL variants have been detected both in normal individuals and in a variety of disease states. 12 The high molecular weight forms which are named `big' (50 ± 60 kda) and `big ± big' (150 kda) PRL are less active in vivo and=or are transported less easily across the capillary bed than the 22 kda molecules. 13 `Big' and `big ± big' PRL (macroprolactinemia) do not appear to contribute to ED. 14,15 For this reason, Cavaco et al. suggest PRL measuring methods which are less sensitive to the presence of `big ± big' PRL in order to differentiate clinically important HP from that caused by macroprolactinemia. 16 The assay used to measure PRL in this study could not exclude macroprolactinemia and was unable to identify which PRL variant was being measured. It is therefore possible that some cases of HP detected in this study could be due to the presence of `big' or `big ± big' PRL. In these cases, the ED may be associated with psychological ED rather than being associated with PRL. A PRL assay insensitive to `big' or `big ± big' PRL would be the ideal method to avoid these issues. The rate of HP obtained in this study (2.2%) ts within the 1 ± 5% range of previous studies. 1,2,9,17 ± 19 Compilation of these studies with ours results in prevalences of PRL greater than 35 ng=ml at 0.9% (28 out of 3265) and of pituitary adenomas at 0.4% (18 out of 4501). If a PRL determination had not been conducted in the 138 cases studied, nine cases of HP above 15 ng=ml, and three cases above 35 ng=ml could have been missed. The cost of conducting a routine PRL measurement in the 138 men was $182 at the incremental cost of $1.32 per determination at this institution (all gures $US). The cost of detecting a single case of severe HP is only $60.72 at this institution. Utilizing a private laboratory in our region, the cost of detecting a case of severe HP in men presenting to the ED clinic would be $851 at a charge of $18.50 per PRL determination. Although it is dif cult to compare costs between institutions with variable cost contributors and billing systems, it is clear that in this environment, a routine PRL
6 level is a relatively inexpensive method of detecting a serious but reversible disease process. Previous studies identi ed PRL levels above 35 ng=ml as markedly high. 2 Our analysis of 138 impotent men showed that two men out of six with PRL levels between 15 and 35 ng=ml were found to have a pituitary microadenoma. Therefore further investigation of the etiology of ED in men with even moderate HP may aid in the initial diagnosis. Finally, this report suggests that with the advent of medication which improves ED without addressing the underlying disorder, a routine PRL measurement in all men presenting to the ED clinic will avoid missing HP. Our case study describes a man who was initially treated with sildena l for ED. Despite the improvement in sexual function with sildena l, the result of a routine PRL measurement was fully investigated at a later time to comply with the routine protocol used in this clinic for the initial assessment of ED. The existence of this protocol was fortunate for the patient as the routine PRL measurement revealed HP. The patient's therapy was then switched to bromocriptine. Thus timely detection of HP allowed treatment of the underlying cause of sexual dysfunction. HP resulting from pituitary adenomas can have serious consequences if left unrecognized. 20 Individuals with such lesions may present with loss of libido, ED, ejaculatory incompetence, reduced seminal volume, gynecomastia, and visual eld disturbances and local compressive symptoms in males. 21 As reported previously, in a series of 22 male patients with PRL-secreting pituitary tumors, 91% had ED and decreased libido. 22 The man in this case study had no clinical signs of HP other than ED, and reported normal libido in response to at least one index of desire used. The absence of clinical markers of HP in such cases illustrates the importance of a full assessment for the cause of ED before any therapy in order to avoid missing the diagnosis of a potentially curable or serious disease. 23 Conclusion Our analysis of 138 men provides systematic evidence to support the `Process of Care' model recommendation that a routine PRL level determination should be conducted in the initial evaluation of ED. 7 Data generated by psychometric indices of desire (such as the SDD of the IIEF and the single question CI) did not serve as a predictor for both mild and severe HP. Low testosterone alone cannot substitute as a predictor for HP. Selective PRL determination based on these indices would result in missed cases of HP. If PRL can only be determined by an institution in select cases, then a low EFD score on the IIEF (below 10) should be included as an additional ag for testing PRL levels. Our data suggests that the safest approach would be to conduct routine PRL measurements in all men presenting to the ED clinic. This becomes especially important in light of the increased use of medications that improve ED (and some that may affect libido) without addressing the underlying pathology. A routine PRL measurement is relatively inexpensive in this environment and early detection of a potentially serious and treatable disease may afford greater therapeutic success. Acknowledgements The assistance of Dr Michael J Raymond (Chief, Clinical Chemistry), and the nancial support from the Queen's University Dean of Medicine, is gratefully acknowledged. References 1 Akpunonu BE et al. Routine prolactin measurement is not necessary in the initial evaluation of male impotence. J Gen Intern Med 1994; 9: 336 ± Buvat J, Lemaire A. Endocrine screening in 1022 men with erectile dysfunction: clinical signi cance and cost-effective strategy. J Urol 1997; 158: 1764 ± Nickel JC et al. Endocrine dysfunction in impotence: incidence, signi cance, and cost-effective screening. J Urol 1984; 132: 40 ± Seftel AD. Editorial: erectile dysfunction Ð the paradigm changes but the challenges remain. J Urol 1997; 156: 1768 ± Garg RK, Khaishgi A, Dandona P. Is management with sildena l changing clinical practice? Lancet 1999; 353: 375 ± Rosen RC et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dyfunction. Urology 1997; 49: 822 ± Padma-Nathan H. Diagnostic and treatment strategies for erectile dysfunction: the `Process of Care' model. Int J Impot Res 2000; 12(Suppl 4): S119 ± S NIH Consensus Development Panel on Impotence. Impotence. JAMA 1993; 270: 83 ± Johnson AR, Jarow JP. Is routine endocrine testing of impotent men necessary? J Urol 1992; 147: 1542 ± Foster RS et al. Role of serum prolactin determination in evaluation of impotent patient. Urology 1990; XXXV1: 499 ± Cappelleri JC et al. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999; 54: 346 ± Sinha YN. Structural variants of prolactin: occurrence and physiological signi cance. Endocrine Rev 1995; 16: 354 ± Leite V et al. Characterization of big ± big prolactin in patients with hyperprolactinemia. Clin Endocrinol 1992; 37: 365 ± Guay AT, Sabharwal P, Varma S, Malarkey WB. Delayed diagnosis of psychological erectile dysfunction because of the presence of macroprolactinemia. J Clin Endocrinol Metab 1996; 81: 2512 ± Tritos NA, Guay AT, Malarkey WB. Asymptomatic `big' hyperprolactinemia in two men with pituitary adenomas. Eur J Endocrinol 1998; 138: 82 ±
7 Cavaco B et al. Hyperprolactinemia due to big ± big prolactin is differently detected by commercially available immunoassays. J Endocrinol Invest 1999; 22: 203 ± Kropman RF et al. Routine endocrine screening in impotence: signi cance and cost-effectiveness. Int J Impot Res 1991; 3: Maatman TJ, Montague DK. Routine endocrine screening in impotence. Urology 1986; 27: Leonard MP, Nickel CJ, Morales A. Hyperprolactinemia and impotence: why, when, and how to investigate. J Urol 1989; 142: Zonszein J. Diagnosis and management of endocrine disorders of erectile dysfunction. Urol Clin N Am 1995; 22: 789 ± Besser GM et al. Clinical and therapeutic aspects of hyperprolactinemia. In: MacLeod RM, Thorner MO, Scapagnini U (eds). Prolactin. Basic and Clinical Correlates. Liviana Press: Padova, 1985, pp 833 ± Carter JN et al. Prolactin-secreting tumors and hypogonadism in 22 men. New Engl J Med 1978; 299: 847 ± Chan-Tack KM. Oral sildena l in erectile dysfunction. Lancet 1998; 352: 1557.
Measurement of erectile dysfunction in population-based studies: the use of a single question self-assessment in the Massachusetts Male Aging Study
(2000) 12, 197±204 ß 2000 Macmillan Publishers Ltd All rights reserved 0955-9930/00 $15.00 www.nature.com/ijir Measurement of erectile dysfunction in population-based studies: the use of a single question
More informationManaging Testosterone Deficiency: A Practical Guide. John Grantmyre MD Professor of Urology Dalhousie University
Managing Testosterone Deficiency: A Practical Guide John Grantmyre MD Professor of Urology Dalhousie University 1 2 Case Study #1 A 59-Year-Old Man with Erectile Dysfunction 3 Case History Robert is a
More informationThe use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction
(2002) 14, 245 250 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic
More information/04/ /0 Reprinted from Vol. 172, , August 2004 THE JOURNAL OF UROLOGY
0022-5347/04/1722-0658/0 Reprinted from Vol. 172, 658 663, August 2004 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2004 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000132389.97804.d7
More informationErectile Dysfunction: A Primer for Primary Care Providers
Erectile Dysfunction: A Primer for Primary Care Providers Jeanne Martin, DNP, ANP-BC Objectives 1. Understand the definition, incidence and prevalence of Erectile Dysfunction in the U.S. 2. Understand
More informationAssessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation
(2001) 13, 41±45 ß 2001 Nature Publishing Group All rights reserved 0955-9930/01 $15.00 www.nature.com/ijir Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation
More informationIC351 (tadalafil, Cialis): update on clinical experience
(2002) 14, Suppl 1, S57 S64 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir IC351 (tadalafil, Cialis): update on clinical experience 1 * 1 Urological practice,
More informationAlternative management of hypogonadism Tamoxifen. Emmanuele A. Jannini, MD Tor Vergata University of Rome ITALY
Alternative management of hypogonadism Tamoxifen Emmanuele A. Jannini, MD Tor Vergata University of Rome ITALY eajannini@gmail.com What hypogonadism is? What hypogonadism is? It is an empty glass The two
More informationOral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction
(2000) 12, Suppl 1, S75±S80 ß 2000 Macmillan Publishers Ltd All rights reserved 0955-9930/00 $15.00 www.nature.com/ijir Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of
More informationERECTILE DYSFUNCTION DIAGNOSIS
ERECTILE DYSFUNCTION DIAGNOSIS Head of Andrology and Sexual Medicine Dep.of Urology and Nefrology Hospital Virgen del Rocío ANDROMEDI. Sexual Medicine SEVILLA. SPAIN General Secretary ESSM Natalio Cruz
More informationSexual dysfunction of chronic kidney disease. Razieh salehian.md psychiatrist
Sexual dysfunction of chronic kidney disease Razieh salehian.md psychiatrist Disturbances in sexual function are a common feature of chronic renal failure. Sexual dysfunction is inversely associated with
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Acquired hypogonadism, prevalence of, 165 167 primary, 165 secondary, 167 Adipose tissue, as an organ, 240 241 Adrenal hyperplasia, congenital,
More informationTestosterone replacement: when is there a role?
(2000) 12, Suppl 4, S112±S118 ß 2000 Macmillan Publishers Ltd All rights reserved 0955-9930/00 $15.00 www.nature.com/ijir Testosterone replacement: when is there a role? 1 * 1 Queens University, Department
More informationAssessment of Erectile and Ejaculatory Function after Penile Prosthesis Implantation
www.kjurology.org DOI:.4/kju.2.5.3.22 Sexual Dysfunction/Infertility Assessment of Erectile and Ejaculatory Function after Penile Prosthesis Implantation Jang Ho Bae, Phil Hyun Song, Hyun Tae Kim, Ki Hak
More informationMechanism of hyperprolactinemia
Hyperprolactinemia Mechanism of hyperprolactinemia Causes of hyperprolactinemia Hormone-producing pituitary tumors Prolactinoma Acromegaly Hypothalamic/pituitary stalk lesion Tumors, cysts (craniopharyngeoma,
More informationHyperprolactinemia: N hidshi i MD. Nahid Shirazian MD. Internist, Endocrinologist
Diagnosis and Treatment of Hyperprolactinemia: p N hidshi i MD Nahid Shirazian MD. Internist, Endocrinologist An Endocrine Society Clinical Practice Guideline (J Clin Endocrinol Metab 96: 273 288, 2011)
More information6/14/2010. GnRH=Gonadotropin-Releasing Hormone.
Male Androgen Replacement Mitchell Sorsby, MD June 19, 2010. QUESTION # 1 Which of the following is not a symptom associated with low T levels? a) decreased libido b) erectile dysfunction c) depression
More informationPrevalence of Erectile Dysfunction in France: Results of an Epidemiological Survey of a Representative Sample of 1004 Men $
European Urology European Urology 42 (2002) 382±389 Prevalence of Erectile Dysfunction in France: Results of an Epidemiological Survey of a Representative Sample of 1004 Men $ FrancËois Giuliano a,*, Marie
More informationHypogonadism and Sexual Dysfunction in Male Cancer Survivors Receiving Chronic Opioid Therapy
Vol. 26 No. 5 November 2003 Journal of Pain and Symptom Management 1055 Clinical Note Hypogonadism and Sexual Dysfunction in Male Cancer Survivors Receiving Chronic Opioid Therapy Arun Rajagopal, MD, Rena
More informationRobotics, Laparoscopy & Endosurgery
Robotics, Laparoscopy & Endosurgery Evaluation of Penile Doppler US and IIEF scoring results in patients with erectile dysfunction due to hypothyroidism after treatment Research Article Sedat Altay 1,
More informationOnset and duration of action of sildena l citrate for the treatment of erectile dysfunction
Onset and duration of action of sildena l citrate for the treatment of erectile dysfunction Ian Eardley, 1 Peter Ellis, 2 Mitradev Boolell 2 & Maria Wulff 2 1 Department of Urology, St James University
More informationLONG-TERM POTENCY AFTER IODINE-125 RADIOTHERAPY FOR PROSTATE CANCER AND ROLE OF SILDENAFIL CITRATE
ADULT UROLOGY CME ARTICLE LONG-TERM POTENCY AFTER IODINE-125 RADIOTHERAPY FOR PROSTATE CANCER AND ROLE OF SILDENAFIL CITRATE RUPESH RAINA, ASHOK AGARWAL, KUSH K. GOYAL, CHERYL JACKSON, JAMES ULCHAKER,
More information/03/ /0 Vol. 170, , July 2003 THE JOURNAL OF UROLOGY. Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION
0022-5347/03/1701-0159/0 Vol. 170, 159 163, July 2003 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000072524.82345.6d COMPARISON OF SATISFACTION
More informationInternational Index of Erectile Function Questionnaire IIEF
International Index of Erectile Function Questionnaire IIEF Instructions: These questions ask about the effects your erections have had on your sex life, over the past 4 weeks. Please answer the following
More informationISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN
International Society for Sexual Medicine - www.issm.info ISSM QUICK REFERENCE GUIDE ON TESTOSTERONE DEFICIENCY FOR MEN Version: September 2015 What is testosterone deficiency? Testosterone deficiency
More informationBPH: a present and future perspective on health impact
BPH: a present and future perspective on health impact Burden of disease in men with moderate LUTS Dalibor Pacík This presentation is financially supported by GlaxoSmithKline. CZ/DUTT/0019/12 Men with
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: erectile_dysfunction 01/01/2019 n/a 01/01/2020 01/01/2019 Policy Effective April 1, 2019 Description of Procedure
More informationClinical evaluation of Tentex forte and Himcolin cream in the treatment of functional erectile dysfunction
Medicine Update (2004): 11(9), 47-51 Clinical evaluation of Tentex forte and Himcolin cream in the treatment of functional erectile dysfunction Dr. Roumen Bostandjiev, Ph.D. Founder and Director of Sexology
More informationErectile dysfunction (ED) is a mutifactorial condition
Journal of Andrology, Vol. 22, No. 5, September/October 2001 Copyright American Society of Andrology Efficacy and Safety of Sildenafil Citrate for Treatment of Erectile Dysfunction in a Population With
More informationThe Investigation and Management of Erectile Dysfunction
Guideline for Administered by the Alberta Medical Association The Investigation and Management of Erectile Dysfunction 00 Update This clinical practice guideline replaces the Alberta Laboratory Endocrine
More informationASSESSMENT OF SEXUAL FUNCTION IN PATIENTS UNDERGOING VASECTOMY USING THE INTERNATIONAL INDEX OF ERECTILE FUNCTION
Clinical Urology International Braz J Urol Official Journal of the Brazilian Society of Urology POST-VASECTOMY SEXUAL FUNCTION Vol. 31 (5): 452-458, September - October, 2005 ASSESSMENT OF SEXUAL FUNCTION
More informationMale Pelvic Health following Pelvic Surgery
Male Pelvic Health following Pelvic Surgery Radical Pelvic Surgery Associated Sexual Dysfunction Pathophysiology Post Radical Prostatectomy (RP) Sexual Dysfunctions Erectile dysfunction (ED) Anejaculation
More informationMetoclopramide Domperidone. HYPER- PROLACTINAEMIA: the true and the false problems
Modern management of Hyperprolactinaemia Didier DEWAILLY, M.D. Department of Endocrine Gynaecology and Reproductive Medicine, Hôpital Jeanne de Flandre, C.H.R.U., 59037 Lille, France 1 Metoclopramide Domperidone
More informationAdministration of Testosterone and its Rationale in the Treatment of Erectile Dysfunction
ORIGINAL ARTICLE Administration of Testosterone and its Rationale in the Treatment of Erectile Dysfunction *CATM Mowladad 1, HM Rafiqul 2, A Bakhtiar 3, KM Rahman 4, R Shofiqur 5 *1 Prof. Chowdhury ATM
More informationSexual Dysfunction. Jae Il Kang, Byeong Kuk Ham, Mi Mi Oh, Je Jong Kim, Du Geon Moon. DOI: /kju
www.kjurology.org DOI:10.4111/kju.2011.52.6.416 Sexual Dysfunction Correlation between Serum Total Testosterone and the AMS and IIEF Questionnaires in Patients with Erectile Dysfunction with Testosterone
More informationA USER S GUIDE WHAT EVERY MAN NEEDS TO KNOW
A USER S GUIDE WHAT EVERY MAN NEEDS TO KNOW 1. Why men need to know more Good health is vital for a happy and full life. But, with work and family responsibilities, men often overlook their own health
More informationORIGINAL ARTICLE Recreational use of erectile dysfunction medication may decrease confidence in ability to gain and hold erections in young males
(2007) 19, 591 596 & 2007 Nature Publishing Group All rights reserved 0955-9930/07 $30.00 www.nature.com/ijir ORIGINAL ARTICLE Recreational use of erectile dysfunction medication may decrease confidence
More informationPatient-reported Sexual Function After Nerve-sparing Radical Retropubic Prostatectomy
European Urology European Urology 42 (2002) 118±124 Patient-reported Sexual Function After Nerve-sparing Radical Retropubic Prostatectomy Joachim Noldus *, Uwe Michl, Markus Graefen, Alexander Haese, Peter
More informationProlactin-Secreting Pituitary Adenomas (Prolactinomas) The Diagnostic Pathway (11-2K-234)
Prolactin-Secreting Pituitary Adenomas (Prolactinomas) The Diagnostic Pathway (11-2K-234) Common presenting symptoms/clinical assessment: Pituitary adenomas are benign neoplasms of the pituitary gland.
More informationHypogonadism 4/27/2018. Male Hypogonadism -- Definition. Epidemiology. Objectives HYPOGONADISM. Men with Hypogonadism. 95% untreated.
Male Hypogonadism -- Definition - Low T, Low Testosterone Hypogonadism -...a clinical syndrome that results from failure of the testes to produce physiological concentrations of testosterone due to pathology
More informationPRISM Bruges June Herman Leliefeld Urologist. The Netherlands
PRISM Bruges 25-26 June 2015 Herman Leliefeld Urologist The Netherlands Guidelines EAU 2015: a rich source of Knowledge! Epidemiology/ Aetiology / Pathology Diagnostic evaluation Disease management Follow-Up
More informationThe Centre for Men s Health
96 Harley Street (London) and Manchester All Enquiries - +44 (0)20 7486 2277 www.centreformenshealth.co.uk/ This leaflet provides information about: The Centre for Men s Health The conditions we treat:
More informationTestosterone Therapy in Men with Hypogonadism
Testosterone Therapy in Men with Hypogonadism (Endocrine Society 2018 Guideline) Ngwe Yin, MD Assistant Clinical Professor of Medicine, UCSF Fresno Medical Education Program Disclosures None Objective
More informationProstate Biopsy Protocol in Active Surveillance for Prostate Cancer Causes ED. Con Man: Andrew McCullough May
Prostate Biopsy Protocol in Active Surveillance for Prostate Cancer Causes ED Con Man: Andrew McCullough May 12 2017 It may be particularly useful as an initial screening instrument in a general practice
More informationPrevalence and Correlates of Erectile Dysfunction in a Population-based Study in Belgium
European Urology European Urology 41 2002) 132±138 Prevalence and Correlates of Erectile Dysfunction in a Population-based Study in Belgium Rudolf Mak a,*, Guy De Backer a, Marcel Kornitzer b, Jean Marie
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) April 2014 Review April 2017 Bulletin 197: Dapoxetine for Premature Ejaculation JPC Recommendations: To support the East of England Priorities Advisory
More informationPituitary Tumors and Incidentalomas. Bijan Ahrari, MD, FACE, ECNU Palm Medical Group
Pituitary Tumors and Incidentalomas Bijan Ahrari, MD, FACE, ECNU Palm Medical Group Background Pituitary incidentaloma: a previously unsuspected pituitary lesion that is discovered on an imaging study
More informationWhat Is the Low T Syndrome? Is Testosterone Supplementation Safe?
What Is the Low T Syndrome? Is Testosterone Supplementation Safe? UCSF Osher Mini Medical School March 7, 2018 Dolores Shoback, MD Staff Physician SF-VAMC Professor of Medicine, UCSF No disclosures or
More informationERECTION HARDNESS: A UNIFYING FACTOR FOR DEFINING RESPONSE IN THE TREATMENT OF ERECTILE DYSFUNCTION
ERECTION HARDNESS: A UNIFYING FACTOR FOR DEFINING RESPONSE IN THE TREATMENT OF ERECTILE DYSFUNCTION JOHN P. MULHALL, LAURENCE A. LEVINE, and KLAUS-PETER JÜNEMANN ABSTRACT The extensive sildenafil citrate
More informationDiagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes
Diagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes Adrian Dobs, M.D., M.H.S. Professor of Medicine and Oncology The Johns Hopkins University School of Medicine
More informationMale circumcision does NOT reduce penile sensitivity. Ira D. Sharlip, M.D. Clinical Professor of Urology UCSF
Male circumcision does NOT reduce penile sensitivity Ira D. Sharlip, M.D. Clinical Professor of Urology UCSF Does male circumcision affect sexual function, sensitivity or satisfaction? a Systematic Review.
More informationSexuality and End Stage Renal Disease
Sexuality and End Stage Renal Disease Information for patients and families Read this information to learn: How Sexuality and End Stage Renal Disease (ESRD) can cause changes in sexuality What changes
More informationAromatase Inhibitors in Male Infertility:
Aromatase Inhibitors in Male Infertility: The hype of hypogonadism? BEATRIZ UGALDE, PHARM.D. H-E-B/UNIVERSITY OF TEXAS COMMUNITY PHARMACY PGY1 03 NOVEMBER 2017 PHARMACOTHERAPY ROUNDS Disclosures No conflicts
More informationEvaluation and Management of Pituitary Failure. Dr S. Ali Imran MBBS, FRCP (Edin), FRCPC Professor of Medicine Dalhousie University, Halifax, NS
Evaluation and Management of Pituitary Failure Dr S. Ali Imran MBBS, FRCP (Edin), FRCPC Professor of Medicine Dalhousie University, Halifax, NS Conflict of Interest None Objectives Diagnostic approach
More informationAn Evidence-based Review of Clinical Trial Data
An Evidence-based Review of Clinical Trial Data Karen K. Miller, MD Massachusetts General Hospital Harvard Medical School Boston, MA 1 Rationale for Investigating Androgen Administration in Women: Data
More informationErectile dysfunction
Erectile dysfunction Good Erectile Function Having good Erections => crucial for all men Because erections & the coitus they allow major pleasure brings self-confidence confirms his state of being a full
More informationPrevalence of anxiety and depressive symptoms in men with erectile dysfunction
Prevalence of anxiety and depressive symptoms in men with erectile dysfunction K Pankhurst, MB ChB G Joubert, BA, MSc P J Pretorius, MB ChB, MMed (Psych) Departments of Psychiatry and Biostatistics, University
More informationThe anocavernosal erectile dysfunction syndrome II Anal ssure and erectile dysfunction
(2000) 12, 279±283 ß 2000 Macmillan Publishers Ltd All rights reserved 0955-9930/00 $15.00 www.nature.com/ijir The anocavernosal erectile dysfunction syndrome II Anal ssure and erectile dysfunction A Sha
More informationDATE: NAME: CLASS: Chapter 14 Test
Multiple Choice Questions Decide which of the choices best completes the statement or answers the question. Locate that question number on the separate answer sheet provided. Use the procedure described
More informationCorporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency
Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testosterone_pellet_implantation_for_androgen_deficiency
More informationSexual dysfunction in men with multiple sclerosis Ð A comprehensive pilot-study into etiology
International Journal of Impotence Research (1998) 10, 233±237 ß 1998 Stockton Press All rights reserved 0955-9930/98 $12.00 http://www.stockton-press.co.uk/ijir Ð A comprehensive pilot-study into etiology
More informationPituitary Adenomas: Evaluation and Management. Fawn M. Wolf, MD 10/27/17
Pituitary Adenomas: Evaluation and Management Fawn M. Wolf, MD 10/27/17 Over 18,000 pituitaries examined at autopsy: -10.6% contained adenomas (1.5-27%) -Frequency similar for men and women and across
More informationGLMS CME- Cell Group 5 10 April Greenlane Medical Specialists Pui-Ling Chan Endocrinologist
GLMS CME- Cell Group 5 10 April 2018 Greenlane Medical Specialists Pui-Ling Chan Endocrinologist Pituitary case one Mrs Z; 64F Seen ORL for tinnitus wax impaction MRI Head Pituitary microadenoma (3mm)
More informationTestosterone and the Prostate
Testosterone and the Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David and Vicki M. Crawford Endowed Chair in Urologic Oncology University
More informationCross-cultural adaptation and validation of the English version of the International Index of Erectile Function (IIEF) for use in Malaysia
(2003) 15, 329 336 & 2003 Nature Publishing Group All rights reserved 0955-9930/03 $25.00 www.nature.com/ijir Cross-cultural adaptation and validation of the English version of the International Index
More informationWhat You Need to Know
UW MEDICINE PATIENT EDUCATION What You Need to Know Facts about male infertility This handout explains what causes male infertility, how it is diagnosed, and possible treatments. Infertility is defined
More informationBIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE
Authoriser: Moya O Doherty Page 1 of 7 BIOCHEMICAL TESTS FOR THE INVESTIGATION OF COMMON ENDOCRINE PROBLEMS IN THE MALE The purpose of this protocol is to describe common tests used for the investigation
More informationEAU GUIDELINES ON MALE HYPOGONADISM
EAU GUIDELINES ON MALE HYPOGONADISM (Limited text update March 2017) G.R. Dohle (Chair), S. Arver, C. Bettocchi, T.H. Jones, S. Kliesch Introduction Male hypogonadism is a clinical syndrome caused by androgen
More informationAndroderm patch, AndroGel packets and pump, Axiron solution, First- Testosterone, First-Testosterone MC, Fortesta gel, Testim gel, Vogelxo
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.31 Subject: Testosterone Topical Page: 1 of 9 Last Review Date: September 23, 2016 Testosterone topical
More informationDiagnosis and management of sexual dysfunction. Dr Chris Simpson Consultant Psychiatrist
Diagnosis and management of sexual dysfunction Dr Chris Simpson Consultant Psychiatrist What are we talking about? Male Erectile dysfunction Premature ejaculation Delayed ejaculation Sexual aversion Paraphilia
More informationIs there a role of radial rigidity in the evaluation of erectile dysfunction?
(2001) 13, 200±204 ß 2001 Nature Publishing Group All rights reserved 0955-9930/01 $15.00 www.nature.com/ijir Is there a role of radial rigidity in the evaluation of erectile dysfunction? JH Ku 1 *, YS
More informationSponsored by. Schering. Sidney Glina
Sponsored by Schering Sidney Glina Testosterone and erectile dysfunction Sidney Glina Keywords Androgen Hormone replacement therapy Hypogonadism Impotence Testosterone Abstract The role of testosterone
More informationLong-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis
(2003) 15, 318 322 & 2003 Nature Publishing Group All rights reserved 0955-9930/03 $25.00 www.nature.com/ijir Long-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction
More informationSurvey on repeat prescribing for acid suppression drugs in primary care in Cornwall and the Isles of Scilly
Aliment Pharmacol Ther 1999; 13: 813±817. Survey on repeat prescribing for acid suppression drugs in primary care in Cornwall and the Isles of Scilly R. BOUTET, M. WILCOCK & I. MACKENZIE 1 Department of
More informationMEN S HEALTH. Selected topics in. Erectile dysfunction Gynaecomastia Late-onset hypogonadism Delayed puberty in males
Selected topics in MEN S HEALTH www.bpac.org.nz keyword: menshealth Erectile dysfunction Gynaecomastia Late-onset hypogonadism Delayed puberty in males 2 September 2010 best tests Erectile dysfunction
More informationEndocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh
Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research
More informationHYPOTHALAMO PITUITARY GONADAL AXIS
HYPOTHALAMO PITUITARY GONADAL AXIS Physiology of the HPG axis Endogenous opioids and the HPG axis (exerciseinduced menstrual disturbances) Effects of the immune system on the HPG axis (cytokines: interleukins
More informationPCa Commentary. Prostate Cancer? Where's the Meat? - A Collection of Studies Supporting the Safety of Its Use. Seattle Prostate Institute CONTENTS
Volume 70 July - August 2011 PCa Commentary SEATTLE PROSTATE INSTITUTE CONTENTS TESTOSTERONE REPLACEMENT in Hypogonadal Men with Treated and Untreated Prostate Cancer? 1 TESTOSTERONE REPLACEMENT in Hypogonadal
More informationDATE BIO# NAME: Last First Middle REFERRING PHYSICIAN NAME: REFERRING PHYSICIAN SPECIALTY (Urologist, Internist, etc.): PRIMARY CARE PHYSICIAN NAME:
DATE BIO# ERECTILE DYSFUNCTION QUESTIONNAIRE NAME: Last First Middle BIRTHDATE: OCCUPATION: REFERRING PHYSICIAN NAME: REFERRING PHYSICIAN SPECIALTY (Urologist, Internist, etc.): PRIMARY CARE PHYSICIAN
More informationCentral hemodynamics and prediction of cardiovascular events in patients with erectile dysfunction
Central hemodynamics and prediction of cardiovascular events in patients with erectile dysfunction N.Skliros, N.Ioakeimidis, D.Terentes-Printzios, C.Vlachopoulos Cardiovascular Diseases and Sexual Health
More informationIan Eardley Department of Urology, Leeds Teaching Hospital Trust
Ian Eardley Department of Urology, Leeds Teaching Hospital Trust Assessment of the man with ED Medical therapy for man with ED What to do when pills fail Sexual stimulus Neural pathways Neurotransmitter
More informationHormone Replacement Therapy
Hormone Replacement Therapy What Role Should It Play With Our Patients? Noel R. Williams MD, FACOG TESTOSTERONE FOR MEN: SALVATION OR SNAKE OIL? Definition Male hypogonadism means the testicles don't produce
More informationPituitary for the General Practitioner. Marilyn Lee Consultant physician and endocrinologist
Pituitary for the General Practitioner Marilyn Lee Consultant physician and endocrinologist Pituitary tumours Anterior/posterior pituitary Extension of adenoma upwards/downwards/sideways Producing too
More informationE cacy, safety and predictive factors of therapeutic success with sildena l for erectile dysfunction in patients with di erent spinal cord injuries
(2001) 39, 637 ± 643 ã 2001 International Medical Society of Paraplegia All rights reserved 1362 ± 4393/01 $15.00 www.nature.com/sc Original Article E cacy, safety and predictive factors of therapeutic
More informationJohn P. Mulhall Peter J. Stahl Doron S. Stember. Clinical Care Pathways in Andrology
John P. Mulhall Peter J. Stahl Doron S. Stember Clinical Care Pathways in Andrology 123 Clinical Care Pathways in Andrology John P. Mulhall Peter J. Stahl Doron S. Stember Clinical Care Pathways in Andrology
More informationThe role of the partner in erectile dysfunction and its treatment
(2002) 14, Suppl 1, S105 S109 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir The role of the partner in erectile dysfunction and its treatment A Riley 1 * 1
More informationL eiaculazione precoce. Giovanni Corona MD, PhD Endocrinology Unit Medical Department, Ospedale Maggiore Bologna, Italy
L eiaculazione precoce Giovanni Corona MD, PhD Endocrinology Unit Medical Department, Ospedale Maggiore Bologna, Italy jocorona@libero.it Corona et al., Nat Rew Urol 2012;9:508 ... ejaculation which always
More informationThe Global Online Sexuality Survey (GOSS) 2015: Erectile Dysfunction Among English-Speaking Internet Users in the United States
Original Article The Global Online Sexuality Survey (GOSS) 2015: Erectile Dysfunction Among English-Speaking Internet Users in the United States Osama Shaeer 1, Kamal Shaeer 2, Mikkel 3, Fode, Ege Serefoglu
More informationThe clinical importance of testosterone in men with type 2 diabetes
22 The clinical importance of testosterone in men with type 2 diabetes GEOFF HACKETT Although the association of low testosterone with type 2 diabetes is well established, testosterone levels are not routinely
More informationLONG-TERM EFFECT OF SILDENAFIL CITRATE ON ERECTILE DYSFUNCTION AFTER RADICAL PROSTATECTOMY: 3-YEAR FOLLOW-UP
ADULT UROLOGY LONG-TERM EFFECT OF SILDENAFIL CITRATE ON ERECTILE DYSFUNCTION AFTER RADICAL PROSTATECTOMY: 3-YEAR FOLLOW-UP RUPESH RAINA, MILTON M. LAKIN, ASHOK AGARWAL, RAKESH SHARMA, KUSH K. GOYAL, DROGO
More informationROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)
ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU) In 1935, Stein and Leventhal described 7 women with bilateral enlarged PCO, amenorrhea or irregular menses, infertility and masculinizing
More informationORIGINAL ARTICLE Importance of screening for macroprolactin in all hyperprolactinaemic sera
Malaysian J Pathol 2013; 35(1) : 59 63 ORIGINAL ARTICLE Importance of screening for macroprolactin in all hyperprolactinaemic sera Farhi Ain JAMALUDDIN, Pavai STHANESHWAR, Zanariah HUSSEIN, Nor ashikin
More informationPrevalence of sexual dysfunction in cases of alcohol dependence syndrome
International Journal of Advances in Medicine Saha A. Int J Adv Med. 2015 May;2(2):110-119 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Research Article DOI: 10.5455/2349-3933.ijam20150507
More informationin Primary Care (Part 2) Jonathan R. Anolik, MD, FACP, FACE Lewis Katz School of Medicine at Temple University
Common Endocrine Problems Seen in Primary Care (Part 2) Lecture #34 Jonathan R. Anolik, MD, FACP, FACE Lewis Katz School of Medicine at Temple University None Conflict of Interest Topics to be Covered
More informationAbout Erectile Dysfunction. Causes, self-test and treatment
About Erectile Dysfunction Causes, self-test and treatment 2015 One Way S.r.l. All rights reserved. Gift copy for physicians. Illustrated by Davide Ceccon With an unrestricted grant from Recordati About
More informationThe Journal of International Medical Research 2012; 40:
The Journal of International Medical Research 2012; 40: 899 908 Comparison of α-blocker Monotherapy and α-blocker Plus 5α-Reductase Inhibitor Combination Therapy Based on Prostate Volume for Treatment
More informationI N T I M A C Y A N D S E X U A L I T Y I N L A T E R L I F E
I N T I M A C Y A N D S E X U A L I T Y I N L A T E R L I F E 2 0 1 6 DESPITE THE COMMON COMPLAINT, EACH PATIENT COMES AS AN INDIVIDUAL, WITH UNIQUE EXPECTATIONS My special interest Counseling patients
More informationEssential advice for men with diabetes from Accu-Chek. Man talk
Essential advice for men with diabetes from Accu-Chek Man talk Diabetes and ere More than 50% of m problems either obtai an erection. Whether you have diabetes or not, erectile dysfunction is a really
More informationQuick Study: Sex Therapy
Quick Study: Sex Therapy Sexual Dysfunction: Difficulty experienced by an individual or couple during the stages of normal sexual activity including physical pleasure, desire, arousal, or orgasm. Assessing
More informationSexual dysfunction in chronic renal failure
QUALITY OF LIFE JNEPHROL 2008; 21 (suppl 13): S113-S117 www.sin-italy.org/jnonline www.jnephrol.com Sexual dysfunction in chronic renal failure Guido Bellinghieri, Domenico Santoro, Agostino Mallamace,
More information